KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $2.9 million.

  • BeOne Medicines' Gains from Investment Securities fell 67.96% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.6 million, marking a year-over-year increase of 38.60%. This contributed to the annual value of $69.4 million for FY2024, which is 23.98% up from last year.
  • Latest data reveals that BeOne Medicines reported Gains from Investment Securities of $2.9 million as of Q3 2025, which was down 95.23% from $61.4 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Gains from Investment Securities registered a high of $175.9 million during Q4 2021, and its lowest value of $478,000 during Q1 2021.
  • Moreover, its 3-year median value for Gains from Investment Securities was $14.7 million (2024), whereas its average is $18.7 million.
  • In the last 5 years, BeOne Medicines' Gains from Investment Securities crashed by 97.45% in 2022 and then skyrocketed by 1,652.11% in 2023.
  • Over the past 5 years, BeOne Medicines' Gains from Investment Securities (Quarterly) stood at $175.9 million in 2021, then tumbled by 97.45% to $4.5 million in 2022, then surged by 200.11% to $13.5 million in 2023, then rose by 8.64% to $14.7 million in 2024, then slumped by 67.96% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $61.4 million for Q2 2025, and $15.7 million during Q1 2025.